The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Cabtreo
clindamycin phosphate/benzoyl peroxide/adapalene · CLINDAMYCIN PHOSPHATE 12 mg/g; BENZOYL PEROXIDE 31 mg/g; ADAPALENE 1.5 mg/g · Gel · Topical · Bausch Health US LLC
NDC 00187-0006-10 · 1 BOTTLE, PUMP in 1 CARTON / 20 g in 1 BOTTLE, PUMP · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00187-0006-25) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$18.58per unit
middle half $18.58–$18.58 · 2 plans · Jul 1, 2024
Est. net of rebatesⓘ
$11.15–$13.93
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
—of plans cover it
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 2 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.0%chance of a new FDA shortage posting for clindamycin phosphate/benzoyl peroxide/adapalene (other) in the next 90 days
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- NDA216632
- TE code
- —
- Approval date
- Oct 20, 2023
- Patents / exclusivity
- 9 patents, 1 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NP | Oct 20, 2026 |
| patent | 11389467 | Dec 28, 2040 |
| patent | 12138278 | Jul 31, 2040 |
| patent | 12133859 | Jul 31, 2040 |
| patent | 12128059 | Jul 31, 2040 |
| patent | 12616710 | Jul 31, 2040 |
| patent | 8288434 | Aug 5, 2029 |
| patent | 10624918 | Jun 3, 2029 |
| patent | 9561208 | Jun 3, 2029 |
| patent | 10220049 | Jun 3, 2029 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class II · TerminatedFeb 12, 2024MCKESSON CORPORATION — CGMP Deviations: Product was stored outside labeled storage temperature requirements. Product was exposed to controlled room temperature environment instead of remaining refrigerated.
Manufacturers of clindamycin phosphate/benzoyl peroxide/adapalene (Gel)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Bausch Health US LLC | CLINDAMYCIN PHOSPHATE 12 mg/g; BENZOYL PEROXIDE 31 mg/g; ADAPALENE 1.5 mg/g | Aug 26, 2026 | Sep 2, 2026 |
| Bausch Health US LLC | CLINDAMYCIN PHOSPHATE 1.5 mg/g; BENZOYL PEROXIDE 31 mg/g; ADAPALENE 12 mg/g | Jul 22, 2026 | Aug 19, 2026 |
| Bausch Health US LLC | ADAPALENE 1.5 mg/g; BENZOYL PEROXIDE 31 mg/g; CLINDAMYCIN PHOSPHATE 12 mg/g | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Cabtreo — NDC 00187-0006-10," retrieved September 3, 2026, https://drugdashboards.com/drug/00187000610.
Free to cite with attribution — see how the data is put together.